Hepatology (Liver, Pancreatic, Gall Bladder) | New Developments

Poseida Therapeutics, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange

Lead Product(s): Gene Therapies

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $110.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 25, 2020

Details:

The expected IPO cash and its series D is earmarked for Poseida's leading candidate P-BCMA-101, an autologous CAR-T currently in a potentially registrational phase 2 trial for multiple myeloma.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Axcella Announces Patent Issuances Covering AXA1665

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

U.S. Patent 10,682,325 covers the composition of AXA1665 as well as other related EMM compositions. U.S. Patent 10,660,870 focuses on methods of use for these EMM compositions in treating a liver disease or disorder involving hyperammonemia and/or muscle wasting.

CN Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Cambridge University

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD

Lead Product(s): AXA1125,AXA1957

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2020

Details:

AXA1125-003 is a clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in adult with nonalcoholic fatty liver disease.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Axcella Completes Enrollment of Subjects in AXA1665-002 Study

Lead Product(s): AXA1665

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2020

Details:

IND submission for overt hepatic encephalopathy and initiation of potential registrational Phase 2b/3 clinical trial planned for second half of 2020.

HepaRegeniX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Boehringer, Novo-backed German biotech banks €11M in liver regeneration push

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: $12.2 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 21, 2020

Details:

The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.

Axcella Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Mileston...

Lead Product(s): AXA1125

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2020

Details:

Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks.

Find

Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

Undisclosed

Product Type

Companies

Poseida Therapeutics, Inc

Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange

Axcella Health

Axcella Announces Patent Issuances Covering AXA1665

CN Bio

CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH

Axcella Health

Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD

Axcella Health

Axcella Completes Enrollment of Subjects in AXA1665-002 Study

HepaRegeniX

Boehringer, Novo-backed German biotech banks €11M in liver regeneration push

Axcella Health

Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Mileston...